Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2594)	11/2/1997 11:31:00 AM
From: JOHN W.	Read Replies (3) of 6136

Subject: Re: Accelerating Sales Date: Sat, Nov 1, 1997 17:04 EST From: Biorich23 Message-id: <19971101220401.RAA17904@ladder01.news.aol.com> 70 by nov. As many who followed the TA of AGPH there was a pattern that developed that had AGPH proceeding to the 70 level by mid-NOV. Re what happened to that pattern was clear. A global stock mkt crash was not factored in, so I hope you understand this. Actually the stock has held up very well and will likely rebound as long as the mkt recovers and moves higher throughout the year. Agouron is likely to see new highs if the mkt rallys because fundamentally we are in a stronger position: 1) We are closer to European Approval as the end of the year approaches. 2) Sales have never been stronger and the more states that approve Viracept only has a jump effrect on this growth: search.main.yahoo.com 3) I hope you have had the opportunity to watch C-span on AIDS treatment and research today. Since Viracept is actually the sole Protease Inhibitor that is federally recommended for the use of treatment of children, 100% acceptance of Viracept on every formulary is mandated. 4) AG3340 data will be released before the end of the year. I have talked to several oncologist/researchers at the trial sites and the company regarding the results seen thus far which have been very exciting. This MMP inhibitor is far superior to British Biotech's (BBIOY) MMP inhibitor that is still in early clinical trials which has a multi-billion market cap for BBIOY . Based on Viracept alone, AGPH is probably 35-45% undervalued. I don't know how you can add a 2B mkt cap biotech value to AGPH based on their MMP inhibitor as BBIOY since they are actually a profitable pharmaceutical company. If you upset that AGPH is not at 70 on the first day of NOV, grow up. Why did you not predict the global stock mkt crash. Your little whinny statement would only have credibility if the mkt never had the last 2 weeks of panic and the world mkt were all at new highs as AGPH fell 10-15%. I would encourage somebody as impatient and ignorant of the global mkts to sell your AGPH shares because their are still many shorts that are looking for a way out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next